GLP-1 Weight Loss Programme (Wegovy / Mounjaro)

Doctor-supervised GLP-1 receptor agonist therapy using Wegovy (semaglutide) or Mounjaro (tirzepatide) with full dose titration, safety screening, side-effect management, and ongoing monitoring.

Accord Medical Clinic offers a medically supervised GLP-1 receptor agonist programme for eligible patients seeking clinically proven weight loss. Dr Joseph Wang prescribes and manages both Wegovy (semaglutide) and Mounjaro (tirzepatide) — the two leading injectable GLP-1 agents available in Singapore — with a structured dose escalation schedule to minimise side effects while maximising efficacy. Wegovy is available from 0.25 mg/month through to the maintenance dose of 2.4 mg/month; Mounjaro from 2.5 mg/month up to 15 mg/month. Both are self-administered as once-weekly subcutaneous injections using pre-filled pens, with the clinic providing full injection training and side-effect management guidance. The programme includes a medical evaluation to confirm eligibility (BMI ≥27 with comorbidities, or BMI ≥30 without), an initial safety blood screen, and regular follow-up consultations to monitor progress and adjust dosing. Most patients see meaningful appetite reduction within 4–8 weeks, with clinical trials demonstrating 10–15% total body weight reduction at full dose. Telehealth follow-up via WhatsApp is available, reducing the need for frequent clinic visits once a patient is stable on their dose. The clinic's integration of GLP-1 therapy with its established acupuncture and diet programme means patients can combine pharmacological and lifestyle approaches within a single care relationship.